Pharmacological treatment strategies of pterygium: Drugs, biologics, and novel natural products

被引：17

作者：

Baheran, Sanaz Sadig ^{[1
]}

Alany, Raid G. ^{[1
,2
]}

Schwikkard, Sianne ^{[1
]}

Muen, Wisam ^{[3
]}

Salman, Lena Namaan ^{[1
]}

Freestone, Nicholas ^{[1
]}

Al-Kinani, Ali A. ^{[1
]}

机构：

[1] Kingston Univ London, Sch Life Sci Pharm & Chem, Drug Discovery Delivery & Patient Care Res Grp, Kingston Upon Thames KT1 2EE, England

[2] Univ Auckland, Sch Pharm, Auckland 1023, New Zealand

[3] Kingston NHS Fdn Trust, Royal Eye Unit, Kingston Upon Thames KT2 7BE, England

来源：

DRUG DISCOVERY TODAY | 2023年 / 28卷 / 01期

关键词：

pterygium; curcumin; chalcone; anti-VEGF; natural products; adjunctive therapy; antioxidant; CONJUNCTIVAL-AUTOGRAFT-TRANSPLANTATION; EXPERIMENTAL CORNEAL NEOVASCULARIZATION; AMNIOTIC MEMBRANE TRANSPLANTATION; MITOMYCIN-C; INFLAMED PTERYGIA; GROWTH-FACTOR; NITRIC-OXIDE; DNA-DAMAGE; CYCLOSPORINE; BEVACIZUMAB;

D O I：

10.1016/j.drudis.2022.103416

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pterygium is a fibrovascular tissue growth invading the cornea. Adjunctive treatment post-surgery includes conventional immunosuppressants as well as antiviral drugs. The use of large-and small-molecule antivascular endothelial growth factor (VEGF) agents remains an integral part of pterygium treatment as well as other neovascular conditions of the eye. Naturally occurring polyphenolic compounds have favorable characteristics for treating neovascular and inflammatory eye conditions, including good efficacy, stability, cost-effectiveness, and the versatility of their chemical synthesis. In this review, we discuss pharmacological treatments of pterygium. Natural products, such curcumin, ellagic acid, and chalcones, are reviewed, with emphasis on their potential as future pterygium treatments.

引用

页数：1

共 108 条

[1] Age-related cataract and drug therapy: opportunities and challenges for topical antioxidant delivery to the lens [J].

Abdelkader, Hamdy ;

Alany, Raid G. ;

Pierscionek, Barbara .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 2015, 67 (04) :537-550

[2] Novel in situ gelling ocular films for the opioid growth factor-receptor antagonist-naltrexone hydrochloride: Fabrication, mechanical properties, mucoadhesion, tolerability and stability studies [J].

Abdelkader, Hamdy ;

Pierscionek, Barbara ;

Alany, Raid G. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2014, 477 (1-2) :631-642

[3] Modern approaches to the ocular delivery of cyclosporine A [J].

Agarwal, Priyanka ;

Rupenthal, Ilva D. .

DRUG DISCOVERY TODAY, 2016, 21 (06) :977-988

[4]

Al-Barrag A, 2010, CLIN OPHTHALMOL, V4, P801

[5] Current concepts and techniques in pterygium treatment [J].

Ang, Leonard P. K. ;

Chua, Jocelyn L. L. ;

Tan, Donald T. H. .

CURRENT OPINION IN OPHTHALMOLOGY, 2007, 18 (04) :308-313

[6] The role of heredity in pterygium development [J].

Anguria, Peter ;

Kitinya, James ;

Ntuli, Sam ;

Carmichael, Trevor .

INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2014, 7 (03) :563-573

[7]

Arain MA, 2012, JCPSP-J COLL PHYSICI, V22, P440, DOI 07.2012/JCPSP.440443

[8] Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal [J].

Ayala, Antonio ;

Munoz, Mario F. ;

Argueelles, Sandro .

OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2014, 2014

[9] Effectiveness to topical ciclosporin A treatment after excision of primary pterygium and limbal conjunctival autograft (vol 31, pg 699, 2008) [J].

Aydin, A. ;

Karadayi, K. ;

Aykan, U. ;

Can, G. ;

Colakoglu, K. ;

Bilge, A. H. .

JOURNAL FRANCAIS D OPHTALMOLOGIE, 2010, 33 (06) :435-435

[10] Quercetin inhibits advanced glycation end product formation via chelating metal ions, trapping methylglyoxal, and trapping reactive oxygen species [J].

Bhuiyan, Mohammad Nazrul Islam ;

Mitsuhashi, Shinya ;

Sigetomi, Kengo ;

Ubukata, Makoto .

BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 2017, 81 (05) :882-890

← 1 2 3 4 5 6 7 8 9 10 →